NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSE AMERICAN:IBIO) (“iBio” or the “Company”) today introduced new cGMP sterile fill-finish capabilities for pharmaceutical products, including monoclonal antibodies, viral vectors, and other biologics. Designed for clients with preclinical and clinical stage programs, the operation is housed in the Company’s 135,000 square foot CDMO facility located in Bryan, Texas.

“Providing Fill-Finish services is a natural extension of iBio’s FastPharming biologics CDMO capabilities,” said Robert Kay, CEO. “Given our ability to quickly deliver GMP and research quantities of active pharmaceutical ingredient (API), the addition of the fill-finish operation completes our rapid, end-to-end service offering.”

The sterile liquid fill-finish operation will incorporate in-line labeling, allowing serialization of vials as they are filled.  Initial capacity supports 100 – 2,500 vials runs, with plans to expand to 15,000.  iBio will be presenting more details on its 5mL vial and 100mL bottle filling services at BIO 2019 in Philadelphia, PA, taking place June 3-6.

“We understand the needs of early stage companies, who often face moving targets for their timelines and support requirements,” commented Nicolas Taquet, Vice President, Biopharmaceutical Manufacturing. “It is often problematic trying to identify available capacity for high-quality, small volume filling. We’re now in position to fill that need for our clients.”

About iBio

iBio is a global leader in plant-based biopharmaceutical contract development and manufacturing services. With iBio’s FastPharming™ protein expression and glycan engineering technologies, consistently high-quality biologics can be produced rapidly in plants using automated hydroponic systems at iBio CDMO, LLC in Bryan, Texas. In addition to GMP contract manufacturing, iBio also offers process development, bioanalytical, and fill-finish services, along with regulatory and facility design consulting as part of an end-to-end solution. For more information, visit www.ibioinc.com.

About BIO International

BIO, taking place June 3-6, 2019 in Philadelphia, PA, features the latest trends, technology, companies, and breakthrough ideas in biotech and pharma. BIO is expecting nearly 16,000 attendees with 1,800 exhibiting companies and delegations from 67 countries Visit iBIO at Booth #3059. For more information about BIO, visit https://convention.bio.org/bio-exhibition/.

FORWARD-LOOKING STATEMENTS

STATEMENTS INCLUDED IN THIS NEWS RELEASE RELATED TO IBIO, INC. MAY CONSTITUTE FORWARD-LOOKING STATEMENTS WITHIN THE MEANING OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995. SUCH STATEMENTS INVOLVE A NUMBER OF RISKS AND UNCERTAINTIES SUCH AS COMPETITIVE FACTORS, TECHNOLOGICAL DEVELOPMENT, MARKET DEMAND, AND THE COMPANY'S ABILITY TO OBTAIN NEW CONTRACTS AND ACCURATELY ESTIMATE NET REVENUES DUE TO VARIABILITY IN SIZE, SCOPE, AND DURATION OF PROJECTS. FURTHER INFORMATION ON POTENTIAL RISK FACTORS THAT COULD AFFECT THE COMPANY'S FINANCIAL RESULTS CAN BE FOUND IN THE COMPANY'S REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION.

Contact:

Stephen Kilmer
Investor Relations
(646) 274-3580 
skilmer@ibioinc.com

ibio (1).jpg

Source: iBio, Inc.

Released June 3, 2019